Arab Finance: The Egyptian International Pharmaceutical Industries Company (EIPICO) reported a 58.8% year-on-year (YoY) increase in consolidated net profit excluding minority interest for the first nine months of 2024, according to the financial income statement filed to the Egyptian Exchange (EGX) on November 13th.

Consolidated net profits logged EGP 903.505 million in the nine months ended September 30th, compared to EGP 568.706 million in the same period of 2023.

Moreover, the company generated consolidated net sales of EGP 5.452 billion in the nine-month period, growing from EGP 3.681 billion in the same period last year.

As per EIPICO’s standalone financial income statement, the company achieved a standalone net profit after tax of EGP 927.696 million in the first nine months of 2024, up from EGP 574.246 million in the year-ago months.

Meanwhile, standalone net sales rose to EGP 5.261 billion from EGP 3.517 billion.

EIPICO is an Egypt-based public shareholding company that operates in the pharmaceutical industry. It is a manufacturer and exporter of pharmaceuticals and holds license agreements with a group of international.

Rameda records 22.17% YoY consolidated profit hike in 9 months Updated 11/14/2024 10:28:00 AM

Alexandria Container’s profit jump 95% YoY in 3 months Updated 11/14/2024 10:25:00 AM

Suez Canal Bank reports 130.07% YoY profit surge in 9 months Updated 11/14/2024 10:22:00 AM

GSK Egypt’s consolidated profit plunges 94.9% YoY in 9 months Updated 11/14/2024 10:07:00 AM

Elsewedy Electric’s consolidated profits hike 64.21% YoY in 9 months Updated 11/14/2024 9:57:00 AM